The Food and Drug Administration approved Genentech's drug Lucentis to treat all forms of diabetic retinopathy — a complication of diabetes that leads to vision loss.
Lucentis represents the first FDA-approved treatment for diabetic retinopathy patients with or without diabetic macular edema.
The FDA previously approved the drug to treat various eye conditions, including wet age-related macular degeneration, diabetic macular edema and myopic choroidal neovascularization.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Bristol-Myers will license drugs to Biogen, Roche for $470M